Published in Medical Letter on the CDC and FDA, December 26th, 2004
On October 22, 2004, the U.S. Food and Drug Administration (FDA) approved the ExAblate 2000 System for the treatment of uterine fibroids. It expedited its review of the device because "it offers significant advantages over existing treatments for uterine fibroids."
ExAblate uses a Magnetic Resonance Imaging (MRI) scanner to identify tissues in the body and assist in planning treatment. During the noninvasive surgical procedure, delivery of high intensity...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.